tirzepatide patent expiry 2036 eli lilly 🚨 Generic Versions of Mounjaro & Zepbound Move Closer as FDA Reviews First Applications The US Food and Drug Administration (FDA) is reviewing the first applications for generic versions of Lilly's Looming GLP-1 drug patent expirations

Luchsinger, J

According to clinical research, the most effective peptide-based weight loss medications are GLP-1 receptor agonists, specifically semaglutide and tirzepatide

10.1007/s00239-004-2666-z 136 TorresM

Tirzepatide appears to have kidney-protective effects based on the Jorge study, but monitoring ensures this holds true individually

Approximately 50% of semaglutide users experience significant weight rebound within one year of stopping the medication, according to clinical follow-up data

The developed pharmacokinetic models of GLP-1 RAs and a dual GLP-1/GIP RA were searched in the PubMed electronic database